Related Experiment Video
Updated: Mar 25, 2026

A Murine Model of Group B Streptococcus Vaginal Colonization
Published on: November 16, 2016
The prevention of early-onset neonatal group B streptococcus infection: New Zealand Consensus Guidelines 2014
Brian Darlow1, Norma Campbell, Nicloa Austin
1CureKids Chair of Paediatric Research at the University of Otago, Christchurch. brian.darlow@otago.ac.nz.
Insights
Group B Streptococcus (GBS) disease prevention in newborns is crucial. A risk-based strategy is recommended for New Zealand, with universal antenatal screening not advised.
Area of Science:
- Neonatal Health
- Infectious Disease Prevention
- Public Health Guidelines
Background:
- Group B streptococcal (GBS) disease is a primary cause of early-onset neonatal sepsis in New Zealand.
- Vertical transmission from mother to infant is the primary route of GBS infection.
- Intrapartum antibiotics can largely prevent GBS disease, with current guidelines based on clinical risk factors.
Framework:
- A multidisciplinary expert group convened to review GBS prevention strategies.
- The review considered a 10-year incidence survey of early-onset GBS neonatal sepsis in New Zealand.
- Literature review and recent national data informed the guideline reassessment.
Implementation:
- The incidence of early-onset GBS sepsis in New Zealand has decreased significantly.
- Missed opportunities for GBS infection prevention were identified.
- Adoption of a national guideline for GBS sepsis prevention and management is proposed.
Implications:
- A risk-based GBS prevention strategy remains the most clinically and cost-effective approach for New Zealand.
- Universal routine antenatal GBS screening is not recommended.
- National guideline adoption aims to further reduce GBS sepsis incidence.
Aims:
Group B streptococcal (GBS) disease is the leading cause of early-onset neonatal sepsis in New Zealand. Disease follows vertical transmission of GBS from the mother, which can largely be prevented by intravenous intrapartum antibiotics. A 2004 New Zealand guideline recommended using clinical risk factors to identify mothers who would qualify for intrapartum antibiotics. An expert multidisciplinary group met to reconsider these guidelines in the light of a two year survey of the incidence of early onset GBS neonatal sepsis.
Methods:
Representatives from the New Zealand College of Midwives, the Fetus and Newborn Committee of the Paediatric Society of New Zealand, the Royal New Zealand College of General Practitioners, the New Zealand Committee of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists, the New Zealand sub-Committee of the Australasian Society of Infectious Diseases, and the Canterbury Home Birth Association met to review the literature and the most recent New Zealand data.
Results:
The multidisciplinary group noted that the estimated incidence of early-onset GBS sepsis had halved over a 10-year period to be 0.26 per 1,000 live births in 2009-11 and that there were missed opportunities for preventing GBS infection. Consensus was reached that adoption of a national guideline on prevention and management of early onset GBS neonatal sepsis by all practitioners and District Health Boards would have the greatest potential to further reduce the incidence.
Conclusion:
A risk-based GBS prevention strategy continues to be recommended as being the most clinically and cost effective for the New Zealand context. Universal routine antenatal GBS screening is not recommended.
Related Concept Videos
Development of the Oral Microbiota
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Development of Human Microbiota
Rh Blood Group
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Rheumatic Heart Disease III: Medical Management

